Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
about
Bisphosphonates for osteoporosis in people with cystic fibrosisBisphosphonates for osteoporosis in people with cystic fibrosisBisphosphonates for osteoporosis in people with cystic fibrosisManagement of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk.Prevention and treatment of systemic glucocorticoid side effects.Bisphosphonates for steroid-induced osteoporosis.Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatmentReproducibility of bone mineral density measurement in daily practiceGlucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment.Pharmacotherapy of osteoporosis in men.Glucocorticoid-induced osteoporosis: treatment update and review.Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis.Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronateManagement of osteoporosis in the aging male: focus on zoledronic acid.Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis.Corticosteroid-induced osteoporosis: an update for dermatologists.A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.Management of glucocorticoid-induced osteoporosis.Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros.Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review.Icariin protects against glucocorticoid-induced osteoporosis in vitro and prevents glucocorticoid-induced osteocyte apoptosis in vivo.Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts.Bone mineral density in children exposed to chronic glucocorticoid therapy.Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation.Effect of Laser Therapy on the Osseointegration of Immediately Loaded Dental Implants in Patients under Vitamin C, Omega-3 and Calcium Therapy
P2860
Q24197936-FCDE0D3B-07D5-494A-A021-A6EEB7CB5D34Q24200401-0BA94E12-D0F4-415D-BD7B-CE43CD45F678Q24239980-915E9932-228B-403E-9D9C-D9CAA0D03575Q30946308-87ED15F3-ECC8-45B1-A85A-1131B51D217EQ33857775-E38163E7-4235-4915-A89B-9C8E6C8722F9Q34542004-AE181DA1-58D9-4485-8266-FBECF686A6E6Q34564319-EF1F6B8B-CB18-47B1-BA48-9D4C491A5ECEQ34790932-980DB0B9-B444-461D-9A14-5ACF5D66136AQ35193628-488231F2-7DAC-42A7-AF8E-381CFF7BE2DEQ35553857-55A411DF-5AA6-4C75-A490-B211D60EEEC0Q35601856-C90AD92D-F72F-4069-ADB9-ACFB816A3D9CQ36040673-3869DCDF-79EE-4DC4-A437-E2C856D54255Q36059394-BBB0DB27-75D3-4F33-834E-AD773F3068F8Q37108645-BC328A2E-E335-4E57-8D97-F1142E27FDEAQ37230770-2B363ED2-2497-453D-9BDF-F918A7DF5754Q37337113-8E86795A-FD08-4F05-9CDD-8B3FCC08E56AQ37374661-D5A2D975-8EE9-445B-AE9C-737BB59F23A3Q37990943-23CA568F-D3D7-4E0A-9D11-210B82042051Q37995500-5C413A81-8B2D-4215-A05E-772A484BEDAAQ38033444-853586AA-45B7-461E-86CA-DBA6E24EE070Q38343436-70D1CAF5-2C55-4626-8406-C6E1D3AB1C2EQ38625982-7CD08DFB-97C9-4015-A0CD-34E20347EA3FQ43824514-51FF8999-9E01-4047-B675-65D340AD1E17Q44057163-027FAB64-A8DC-4D35-9F41-70297C54715EQ46672425-2FBF079A-D7FD-4DC8-9230-4FFCB267DB67Q46772652-BE163A65-0D9B-4E34-8C69-1A0111113EBBQ58777047-9DB82E37-7EB8-4297-9051-179A48BF05FC
P2860
Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Primary prevention of glucocor ...... y 3 months, and calcium alone.
@ast
Primary prevention of glucocor ...... y 3 months, and calcium alone.
@en
type
label
Primary prevention of glucocor ...... y 3 months, and calcium alone.
@ast
Primary prevention of glucocor ...... y 3 months, and calcium alone.
@en
prefLabel
Primary prevention of glucocor ...... y 3 months, and calcium alone.
@ast
Primary prevention of glucocor ...... y 3 months, and calcium alone.
@en
P2093
P1476
Primary prevention of glucocor ...... y 3 months, and calcium alone.
@en
P2093
Devogelaer JP
Esselinckx W
P304
P356
10.1359/JBMR.2001.16.1.104
P577
2001-01-01T00:00:00Z